ADJUVANT OOPHORECTOMY VERSUS CMF FOR PREMENOPAUSAL, NODE-POSITIVE, HORMONE RECEPTOR POSITIVE PATIENTS

被引：0
|
作者：
BETHUNE, WA
机构：
来源：
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION | 1991年 / 83卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：660 / &
相关论文
共 50 条
  • [1] Adjuvant oophorectomy versus CMF in premenopausal node-positive breast cancer:: Long-term results of an experience at the Milan Cancer Institute
    Salvadori, B
    Celio, L
    Oriana, R
    Bajetta, E
    [J]. TUMORI, 2000, 86 (03) : 258 - 259
  • [2] Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer
    Atkins, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3916 - 3917
  • [3] Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer - In reply
    Levine, M
    Pritchard, K
    Bramwell, V
    Shepherd, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3917 - 3917
  • [4] Dose intensity of standard adjuvant cmf with G-CSF for premenopausal node-positive breast cancer patients.
    de Graaf, H
    Willemse, PHB
    Bong, SB
    Piersma, H
    Tjabbes, T
    van Veelen, H
    Coenen, JLLM
    de Vries, EGE
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 : S5 - S5
  • [5] Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: A Southwest Oncology Group study
    Rivkin, SE
    Green, S
    OSullivan, J
    Cruz, AB
    Abeloff, MD
    Jewell, WR
    Costanzi, JJ
    Farrar, WB
    Osborne, CK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 46 - 51
  • [6] Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients
    CastiglioneGertsch, M
    Goldhirsch, A
    Gusterson, B
    Bettelheim, R
    Reed, R
    Gussett, H
    Geiser, K
    Hurny, C
    Bernhard, J
    Hangartner, A
    Maibach, R
    Pedowski, R
    Gelber, R
    Price, K
    Peterson, H
    Zelen, M
    Isley, M
    Hinkle, R
    Kay, RG
    Holdaway, IM
    Harvey, VJ
    Jagusch, MF
    Neave, L
    Mason, BM
    Evans, B
    Benjamin, CS
    Carter, JF
    Gillman, JC
    Mack, D
    BensonCooper, D
    Monfardini, S
    Galligioni, E
    Crivellari, D
    Buonadonna, A
    Massarut, S
    Rossi, C
    Candiani, E
    Carbone, A
    Volpe, R
    Trovo, MG
    Roncadin, M
    Santini, GF
    Villalta, D
    Coran, F
    Morassut, S
    Marini, G
    Simoncini, E
    Marpicati, P
    Zaniboni, A
    Sartori, U
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1885 - 1894
  • [7] Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer
    deGraaf, H
    Willemse, PHB
    Bong, SB
    Piersma, H
    Tjabbes, T
    vanVeelen, H
    Coenen, JLLM
    deVries, EGE
    [J]. ONCOLOGY, 1996, 53 (04) : 289 - 294
  • [8] INTRAVENOUS OR ORAL ADJUVANT CMF FOR NODE-POSITIVE BREAST-CANCER
    LINDEMAN, GJ
    BOYAGES, J
    DRIESSEN, C
    LANGLANDS, AO
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1992, 62 (07): : 556 - 562
  • [9] Leuprorelinacetate 3 month-depot versus CMF as adjuvant treatment in receptor- and node-positive premenopausal patients with breast cancer: long term results of the TABLE-study
    Schmid, P
    Possinger, K
    Kassjanenko, I
    Vassiljev, L
    Meurer, J
    Tschaika, M
    Maubach, L
    Wallwiener, D
    Kahlert, S
    Untch, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S99 - S99
  • [10] Goserelin in versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 Trial
    Von Minckwitz, G
    Graf, E
    Geberth, M
    Eiermann, W
    Jonat, W
    Conrad, B
    Brunnert, K
    Gerber, B
    Zippel, HH
    Kaufmann, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 11S - 11S
12345